Concretely, we examined the therapeutic utility of plasma HSP90α in 130 AGC patients receiving PD-1 inhibitor treatment and found that the short-term effectiveness of GC patients was strongly correlated with dynamic changes in plasma HSP90α. This evidence concerns the gene HSP90AA1 and gastric cancer.